Medication info

Bonbiron Injection (Ibandronate Sodium Trihydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
A colorless and transparent solution contained in a colorless and transparent glass prefilled syringe, with an attached single-use injection needle.
Packaging
3 mL/prefilled syringe × 1 unit
Approval status
Active

MFDS item code 201501299 · Notified 2015.03.12 · Insurance code 648103561

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing day, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Older adults No dosage adjustment is necessary.
Child administration
Efficacy and safety have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medicine is used for the treatment of osteoporosis, which commonly occurs in postmenopausal women. Osteoporosis is a condition in which bones become weak and are at high risk of fractures. This medication helps maintain bone strength and reduces the risk of fractures. Consistent use and management help improve bone health.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing day, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Administration of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Older adults No dosage adjustment is necessary.

Child administration

Efficacy and safety have not been studied in children 18 years of age or younger.

Precautions

This drug must be administered intravenously, and great care must be taken to avoid incorrect administration into arteries or around veins, as it may cause tissue damage. It should not be used in patients with an allergy to this drug or its components or in patients with untreated hypocalcemia. Side effects such as gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, myalgia, arthralgia, headache, and rash may occur while using this drug. In some patients, flu-like symptoms such as fever, chills, fatigue, myalgia, and arthralgia may occur, but they are usually mild and transient. Hypocalcemia or bone and mineral metabolism disorders should be treated before administering this drug, and sufficient intake of calcium and vitamin D is important. Serious side effects such as osteonecrosis of the jaw have been rarely reported, and particularly in patients with cancer or those taking certain medications, it is recommended to consult a specialist before dental treatment. During treatment, excessive dental procedures should be avoided, and if osteonecrosis of the jaw is suspected, inform the healthcare provider immediately. This medication may cause serious side effects, such as inflammation of the eyes, severe allergic reactions, skin diseases, and atypical fractures, and if these symptoms appear, consult the healthcare provider immediately. Patients with impaired kidney function or those taking medications that affect the kidneys need regular monitoring during treatment. If this drug is overdosed, kidney and liver functions should be closely monitored, and calcium or phosphorus supplementation should be received if necessary. It is safer not to use this drug in women who are pregnant or breastfeeding. Its safety and efficacy have not been established in children, and it should not be used in this population. This drug should not be mixed with other intravenous medications and must be administered solely by intravenous injection. Used syringes and needles should not be reused and should be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical non-traumatic fracture, intertrochanteric femoral fracture, osteonecrosis of the external auditory canal, osteonecrosis of the jaw, sensory impairment, acute renal failure, dizziness, optic atrophy, lower motor neuron disease, tremor, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, dental pain, hyperventilation, cough, dyspnea, laryngitis, vulvitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that can block air and moisture. It is best to keep the storage temperature at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

A colorless and transparent solution contained in a colorless and transparent glass prefilled syringe, with an attached single-use injection needle.

Package unit

3 mL/prefilled syringe × 1 unit

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.